Difference between revisions of "Part:BBa K5382150:Experience"

Revision as of 09:45, 30 September 2024

This experience page is provided so that any user may enter their experience using this part.
Please enter how you used this part and how it worked out.

Applications of BBa_K5382150

We conducted cellular genome editing experiments to assess the efficiency of a targeted delivery system. Initially, OMVs loaded with Cas9 RNPs were introduced into HeLa cells to target the PRDX4 gene and evaluate Indel editing efficacy. Subsequently, CL7-fused transmembrane peptides and/or monoclonal antibodies were applied to these cells in order to determine their cellular targeting effectiveness and gene editing capabilities. By employing the T7 endonuclease I (T7E1) assay, we confirmed that the engineered OMV-Cas9 RNP complex exhibits genome editing activity comparable to that of commercial lipid-based transfection agents, as depicted in Figure 1.

Figure. 1 The assessment of genome-editing efficiency in HeLa cells using the T7E1 method.

Our findings suggest that OMVs containing Cas9 RNPs have a gene editing efficiency comparable to commercial lipid transfection reagents, achieving a target gene cleavage rate of around 40%. In vitro cell targeting assays highlight the significant gene editing capabilities of our engineered self-assembling system incorporating Cas9 RNPs. Compared to traditional methods for preparing Cas9 RNPs, our system offers notable advantages including the elimination of separate crRNA synthesis and the facilitation of efficient and cost-effective production of stable Cas9 RNP complexes on a large scale through a simplified purification protocol. These results imply that our system is suitable for a wider range of applications.

User Reviews

UNIQc4b69b46b6740e18-partinfo-00000000-QINU UNIQc4b69b46b6740e18-partinfo-00000001-QINU

@@ Line 5: / Line 5: @@
 ===Applications of BBa_K5382150===
-Extrudable outer membrane vesicles containing Cas9 RNP were delivered into HeLa cells, and the gene-editing activity of prepared OMV-Cas9 RNP was compared with commercial liposomal transfection reagents by T7E1 assay (FIG. 1).<br>
+We conducted cellular genome editing experiments to assess the efficiency of a targeted delivery system. Initially, OMVs loaded with Cas9 RNPs were introduced into HeLa cells to target the PRDX4 gene and evaluate Indel editing efficacy. Subsequently, CL7-fused transmembrane peptides and/or monoclonal antibodies were applied to these cells in order to determine their cellular targeting effectiveness and gene editing capabilities. By employing the T7 endonuclease I (T7E1) assay, we confirmed that the engineered OMV-Cas9 RNP complex exhibits genome editing activity comparable to that of commercial lipid-based transfection agents, as depicted in Figure 1.<br>
-https://static.igem.wiki/teams/5382/part-pictures/gene-editing1.png<br>'''Figure 1.'''Verification experiment of genome editing activity of Hela cells.<br>
-The results of cutting the target gene showed that the prepared OMV-Cas9 RNP had similar genome editing activity to the commercial liposome transfection reagent, both of which were about 40%.
+https://static.igem.wiki/teams/5382/part-pictures/16.png<br>'''Figure. 1''' The assessment of genome-editing efficiency in HeLa cells using the T7E1 method.<br>
+ Our findings suggest that OMVs containing Cas9 RNPs have a gene editing efficiency comparable to commercial lipid transfection reagents, achieving a target gene cleavage rate of around 40%. In vitro cell targeting assays highlight the significant gene editing capabilities of our engineered self-assembling system incorporating Cas9 RNPs. Compared to traditional methods for preparing Cas9 RNPs, our system offers notable advantages including the elimination of separate crRNA synthesis and the facilitation of efficient and cost-effective production of stable Cas9 RNP complexes on a large scale through a simplified purification protocol. These results imply that our system is suitable for a wider range of applications.
 ===User Reviews===